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In Brief Rittiner and Caffall et al. demonstrate that deficiencies in eukaryotic initiation factor 2a (eIF2a) signaling-known for roles in cellular stress and synaptic plasticityare found in multiple types of dystonia, caused by independent molecular mechanisms in each form of the disease.
INTRODUCTION
Dystonia is a centrally driven movement disorder characterized by sustained involuntary postures and/or slow twisting movements that lead to motor disability and pain. Clinical presentations range from focal dystonias that affect a single body part to generalized forms that involve most of the body and can severely limit the ability to be independent in activities of daily living (Waugh and Sharma, 2013) . Collectively, dystonia is the third most common movement disorder, and can arise in many contexts, limb trauma, traumatic brain injury, stroke, neurodegenerative diseases, antipsychotic medication use, rare inherited syndromes, and ''sporadically'' Defazio, 2010) . Presently, at least 24 genetic loci have been associated with isolated or combined heritable dystonias (Balint and Bhatia, 2015) . While some cellular processes are implicated by those dystonia-associated genes for which there are known functions, the cellular mechanisms for dystonia remain largely unknown (Bragg et al., 2011; Lohmann and Klein, 2013) . In addition, because there are both diverse causes and diverse clinical presentations of dystonia, it is further unknown whether distinct forms of dystonia may share common mechanisms. To date, dopamine deficiency is the only cellular pathomechanism for which there is support across multiple forms of dystonia (Lohmann and Klein, 2013; Waugh and Sharma, 2013) .
As the need to understand disease mechanisms extends beyond Mendelian disorders with strong effect sizes and as genome-wide data sets become readily accessible, a promise and challenge of functional genomics is to integrate functional and genetic data to advance our understanding and treatment of disease. Here, we applied results from a high-throughput phenotypic screen based on a rare Mendelian genetic disease to whole exomic sequence (WES) data from a small cohort of patients with sporadic disease and uncovered a cellular mechanism for dystonia pathogenesis that spans multiple forms of the disorder. Functional studies including patient-derived cell lines and genetic mouse models combined with consideration of the putative activity of PRKRA mutations found in another inherited generalized dystonia, DYT16, support a consistent directionality of reduced eukaryotic initiation factor 2a (eIF2a) pathway signaling as a mechanism for dystonia. The eIF2a pathway is a ubiquitous cellular pathway widely known as the integrated stress response, or ISR Wek et al., 2006) , and is also required in the brain for synaptic plasticity (Trinh and Klann, 2013) .
DYT1 dystonia is a rare, early-onset, generalized form of dystonia. DYT1 is caused by an in-frame trinucleotide deletion in the TOR1A gene, leading to loss of a glutamic acid residue (DE) from the AAA+ ATPase Torsin1a (Ozelius et al., 1997) . Both the normal function of Torsin1a and significance of the mutant protein for disease pathogenesis have been intensively studied and at least five cellular processes have been suggested, including roles in nuclear transport, synaptic vesicle cycling, lipid metabolism, and endoplasmic reticulum (ER) stress Chen et al., 2010; Granata et al., 2011 Granata et al., , 2008 Grillet et al., 2016; Jokhi et al., 2013; Nery et al., 2011) . Although the precise cellular function(s) of Torsin1a and the pathogenic mechanism of DE Torsin1a remain uncertain, multiple independent laboratories have observed that the DE mutation has a dramatic effect on Torsin1a subcellular localization (Bragg et al., 2004; Calakos et al., 2010; Giles et al., 2008; Gonzalez-Alegre and Paulson, 2004; Dauer, 2005, 2004; Hewett et al., 2000 Hewett et al., , 2008 Kustedjo et al., 2000; Liang et al., 2014; Vander Heyden et al., 2009; Vulinovic et al., 2014) .
Normally, wild-type (WT) Torsin1a cycles between the outer nuclear envelope (NE) and ER lumen in an ATP-dependent fashion, with the bulk of the protein detected in the ER (Goodchild and Dauer, 2004; Naismith et al., 2004) . In contrast, when DE Torsin1a is the major species, as in overexpression experiments or homozygous knockin mouse models, it predominantly co-localizes with nuclear envelope markers and disrupts the normal subcellular NE membrane structure in a manner that is suggestive of a membrane-trafficking defect (Goodchild and Dauer, 2004; Jokhi et al., 2013; Naismith et al., 2004 ). At the light microscopic level, DE Torsin1a distribution appears as an abnormal punctate pattern ( Figure 1A) .
In this study, we took advantage of the robust and proximal phenotype of DE Torsin1a mislocalization to develop a highthroughput assay to identify cellular signaling pathways involved in remediating mutant Torsin1a mislocalization. We hypothesized that pathway perturbations which correct DE Torsin1a mislocalization could serve as novel therapeutic targets for DYT1 dystonia. We then applied the assay to conduct a genome-wide RNAi screen and used the results to generate unbiased hypotheses for mechanisms of dystonia.
RESULTS

Development and Validation of DE Torsin1a Localization Assay
We generated two human HEK293T cell lines that stably expressed either EGFP-tagged human WT or DE Torsin1a from a cDNA integrated at a defined genomic site under inducible control by tetracycline (see Supplemental Experimental Procedures and Figure S1 ). Using this expression system, WT and DE Torsin1a lines consistently reproduced their respective subcellular localization phenotypes ( Figures 1A and 1B) . The mutant phenotype was measured as the percentage of cells with one or more EGFP puncta using automated high-content imaging analysis (''% selected cells''; see Figure S2 ).
We first tested the predictive validity of the automated readout in corroborating existing observations regarding Torsin1a biology. Compensation by the homologous protein, Torsin1b, is hypothesized to underlie the selective vulnerability of the brain where Torsin1b levels are low (Jungwirth et al., 2010; Kim et al., 2010; Tanabe et al., 2016) . Consistent with this model, knock down of Torsin1b significantly increased Torsin1a mislocalization in both cell lines ( Figure 1C ). Second, Torsin1a protein levels have also been hypothesized to contribute to DYT1 dystonia pathogenesis (Bragg et al., 2004; Goodchild and Dauer, 2004; Grundmann et al., 2007) . Inhibiting protein clearance with the proteasome inhibitor MG132 significantly increased the percentage of cells with punctate EGFP-Torsin1a signal in both cell lines (Figure 1D) . Lastly, DE Torsin1a has been associated with activation of the unfolded protein response (UPR) (Bragg et al., 2011; Chen et al., 2010; Hewett et al., 2007; Nery et al., 2011) , and in DYT1 patient-derived fibroblasts, the chemical chaperone, phenylbutyric acid (PBA) reduces indicators of UPR activation (Cao et al., 2010) . In our assay cell lines, we found that PBA significantly reduced punctate pathology ( Figure 1D ). Thus, although the biological significance of DE Torsin1a mislocalization in DYT1 dystonia pathogenesis is unknown, Torsin1a localization phenotypes predict known Torsin1a biology and suggests this phenotypic screen may be a useful tool to advance our understanding of the mechanisms by which DE Torsin1a disrupts cell function.
Genome-wide Small Interfering RNA Screen to Correct DE Torsin1a Mislocalization A pilot screen of 960 genes was performed to establish proof-ofprinciple that gene knockdown using small interfering (si)RNA could normalize DE Torsin1a distribution ( Figures 1E-1G) . We then performed a whole genome screen (WGS) targeting 22,909 human genes (QIAGEN Whole Genome siRNA KnockDown Library 1.0). There were four siRNAs targeting each gene that were tested in a paired-screen design of two independent pools of two siRNAs each ( Figure 1H ) (Barrows et al., 2010) . Hits were defined as those genes whose siRNAs concordantly improved DE Torsin1a localization by at least three SDs in both of the two unique siRNA pools (Figure 1I, yellow) . No microRNA seed sequences were significantly enriched among screen hits (Sigoillot et al., 2012 ) (www.flyrnai.org/gess). In addition, hits that were cytotoxic, significantly decreased EGFP-Torsin1a expression, or were not expressed in the assay cell line (as determined by microarray analysis; see GEO: GSE89180) were discarded (see Supplemental Experimental Procedures for detail). The primary images were then examined by blinded scorers and ranked to identify those hits that resulted in typical wildtype Torsin1a distribution. The resulting group was used for pathway analysis and consisted of 93 high-stringency and high-quality hits ( Figure 1J ; Table S1 ).
Hit Validation and Bioinformatic Analysis
To cross-validate WGS hits in a system that did not rely upon exogenous expression of Torsin1a or a fusion protein, we tested four of the highest-quality hits in an orthogonal counter screen using patient-derived fibroblasts. We tested each small hairpin (sh)RNA for its ability to rescue a previously described defect in luciferase secretion (Cao et al., 2010; Hewett et al., 2007; Nery et al., 2011) and found that three of the four hits tested (K) Luciferase secretion in DYT1 patient-derived fibroblasts after lentiviral delivery of shRNAs targeting four top WGS hits. n = 4 DYT1 lines and 3 control lines, five independent replicates each (except SCD, three replicates). *p < 0.05 and ***p < 0.0005 by unpaired t test. All of the data are presented as means ± SEM. also improved this DYT1-related phenotype ( Figure 1K ). We then conducted bioinformatic analysis, which identified 11 significantly overrepresented signaling pathways (Table 1) .
The most enriched pathway among WGS hits-as well as among hits derived from a less stringent analysis (R2 SD effect size; see Table S2 )-was eIF2a signaling, also known as the ISR (Figure 2A ) Wek et al., 2006) . Briefly, in the ISR, eIF2a, the rate-limiting regulatory subunit of the eIF2 complex, which mediates the binding of methionyl-tRNA to the ribosome to begin protein translation (Hinnebusch and Lorsch, 2012) , is phosphorylated by any of four upstream stress-sensitive kinases. Phosphorylation of eIF2a has two main effects: a general decrease in protein translation and an increased translation of a subset of transcripts containing upstream open reading frames (uORFs) (Jackson et al., 2010; Vattem and Wek, 2004) . Principal among the transcripts whose translation is upregulated is ATF4, a transcription factor that stimulates the expression of stress response proteins (Harding et al., 2000; Vattem and Wek, 2004) . Eukaryotic initiation factor 2a signaling also leads to expression of protein phosphatase 1 regulatory subunits CReP and GADD34, which dephosphorylate eIF2a and terminate ISR activation (Jousse et al., 2003; Novoa et al., 2001 ).
Pharmacological Manipulation of eIF2a Signaling
Bidirectionally Regulates Torsin1a Localization Although our screen implicated eIF2a signaling, the hits that yielded the bioinformatics result ( Figure 2B , blue) did not reveal the directionality of the signaling change normalizing DE Torsin1a localization. However, knock down of each of the four eIF2a kinases significantly worsened DE Torsin1a localization (Figures 2A and 2B) , indicating that decreased eIF2a signaling has a deleterious effect. These results also suggest then that promoting eIF2a pathway signaling would be beneficial.
In order to test this model directly, we treated the DE Torsin1a cell line with compounds targeting the eIF2a signaling pathway (Figure 2A , blue). Salubrinal, a drug that prolongs ISR activation by inhibiting eIF2a dephosphorylation (Boyce et al., 2005) , caused a robust dose-dependent normalization of DE Torsin1a localization, without modifying steady-state EGFP-Torsin1a levels or causing toxicity at effective concentrations ( Figure 2C ). As a control, vehicle treatment (DMSO) at concentrations present in these experiments had no effect on cell pathology or number ( Figures 2D and S3) . None of the compounds tested significantly altered steady-state levels of EGFP-Torsin1a (Figure 2, green) . Interestingly, another eIF2a phosphatase inhibitor, guanabenz, had no effect on DE Torsin1a localization ( Figure 2E ). Guanabenz is a more selective inhibitor of GADD34-containing than CReP-containing eIF2a phosphatase complexes (Tsaytler et al., 2011) . Sephin 1, another GADD34-specific inhibitor that lacks guanabenz's off-target adrenergic activity, also had no effect on DE Torsin1a localization (data not shown). We next examined the efficacy of a direct activator of the eIF2a kinase PERK, CCT020312 (Stockwell et al., 2012) . CCT020312 also caused a dose-dependent reduction in the number of cells with Torsin1a inclusions ( Figure S4 ), but treatment was highly toxic at effective concentrations, as indicated by cell count and morphology ( Figure S4 ). Thus, collectively, these experiments suggest that positive modulation-as opposed to direct activation-of eIF2a signaling may be more easily tolerated and therefore more likely to be of therapeutic value.
Upon finding that prolonged signaling through eIF2a phosphorylation normalizes DE Torsin1a distribution (as in Figure 2C ), we next asked whether preventing such signaling would alter the normal distribution of Torsin1a. To do this, we tested effects of ISRIB, a compound that prevents the downstream signaling consequences of eIF2a phosphorylation (Sidrauski et al., 2015 (Sidrauski et al., , 2013 on the WT Torsin1a assay cell line. ISRIB caused a dose-dependent increase in cells with punctate Torsin1a localization without altering Torsin1a levels ( Figure 2F ; for DMSO control in WT Torsin1a cell line; see Figure S3 ). These findings indicate a dynamic role for the ISR pathway in bidirectionally regulating Torsin1a localization.
Finally, we tested compounds targeting alternative signaling pathways that could potentially mediate the effects upon Torsin1a localization, including two additional pathways enriched among the WGS hits, notch signaling and glucocorticoid signaling. Treatment with the g-secretase inhibitor, DAPT, which blocks notch signaling, had no effect on DE Torsin1a localization ( Figure 2G ), nor did the anticonvulsant, valproic acid, which, among other activities, activates notch signaling ( Figure S5 ). Similarly, neither the glucocorticoid receptor agonist dexamethasone ( Figure 2H ) nor a small panel of additional compounds modulating glucocorticoid/mineralocorticoid receptor signaling ( Figure S5 ) significantly modified DE Torsin1a localization. Next, because PERK-mediated eIF2a signaling is one of three branches of the unfolded protein response (Patil and Walter, 2001) , we tested modulators that are available for another branch, which requires ATF6 signaling. We found that compounds targeting this branch primarily caused cytotoxicity (Figure S6) . Furthermore, knock down of ATF6 did not significantly normalize or worsen DE Torsin1a localization in the WGS screen. Finally, since salubrinal has been shown to inhibit NF-kB signaling in addition to its effects on the eIF2a pathway (Nakajima et al., 2015), we tested compounds that both activate and inhibit the NF-kB pathway. As with ATF6 signaling, we found that compounds targeting the NF-kB pathway were principally cytotoxic ( Figure S6 ). Together, these results identify augmentation of signaling through the eIF2a pathway as a specific, efficacious, and non-toxic target to normalize DE Torsin1a mislocalization.
Expression of ATF4 Is Sufficient to Normalize DE Torsin1a Localization
We next considered the mechanisms downstream of eIF2a phosphorylation that might mediate normalization of DE Torsin1a localization. Phosphorylation of eIF2a has two downstream consequences: a general decrease in translation and an increase in translation of a subset of transcripts containing uORFs, the most well-characterized of which is the transcription factor ATF4 (Figure 2A ) (Vattem and Wek, 2004) . Therefore, to determine if increased ATF4 expression alone was sufficient to normalize DE Torsin1a localization, we overexpressed ATF4 in the DE Torsin1a assay cell line. ATF4 overexpression significantly improved DE Torsin1a localization, with negligible effects on WT Torsin1a localization ( Figure 3A) . Furthermore, overexpression of an ATF4 point mutant, which cannot bind DNA, R296K (Aukerman et al., 1991) , had no effect ( Figures 3A and  3B , right).
eIF2a Signaling Is Required for LTD at Corticostriatal Synapses and Enhancing eIF2a Signaling Rescues Deficient Corticostriatal LTD in DYT1 Knockin Mice
We next examined whether there was evidence of eIF2a pathway dysfunction in a setting that did not involve exogenously expressed Torsin1a, mimicked the human genotype (heterozygosity), and involved the brain. Dystonia is a brain disorder and although a disturbed ER stress response is a plausible mechanism for CNS disease, eIF2a phosphorylation is also known to have brain-specific roles in long-term synaptic plasticity (Costa-Mattioli and Sonenberg, 2006; Di Prisco et al., 2014; Trinh and Klann, 2013) . Coincidentally, disrupted synaptic plasticity in basal ganglia circuitry has long been hypothesized as a disease mechanism for dystonia (reviewed in Peterson et al., 2010) . Furthermore, DYT1 mouse models have disruptions of long-term synaptic plasticity in the striatum, absence of type 5 metabotropic glutamate receptor (mGluR5)-dependent longterm synaptic depression (LTD), and increased long-term potentiation (LTP) magnitude (Martella et al., 2014 (Martella et al., , 2009 ). In the hippocampus, eIF2a phosphorylation is required for mGluR-dependent LTD (Di Prisco et al., 2014) and shifts that reduce the amount of phosphorylated protein have been previously hypothesized to lower the threshold for LTP (Costa-Mattioli et al., 2007) . Thus, known brain-specific eIF2a roles directly correlate with previously well-described alterations in DYT1 mouse model synaptic plasticity. To directly test these predictions, we performed whole-cell electrophysiology of striatal projection neurons in acute brain slices to induce long-term depression in the presence of eIF2a pathway-modulating drugs. We first assessed whether eIF2a signaling normally plays a role in striatal mGluR5 LTD. We found that pre-incubation with ISRIB (5 nM), a blocker of eIF2a pathway signaling, robustly inhibited LTD in WT brain slices ( Figure 4A ). Additionally, it was notable that while control vehicle-treated slices display a range of responses, none were greater than the baseline amplitude; however, in the presence of ISRIB, potentiating responses were now observed.
To test whether augmenting eIF2a signaling in DYT1 model mice would normalize synaptic plasticity, we similarly treated brain slices from heterozygous DYT1 knockin mice (delGAG) with 20 mM Sal-003, an analog of salubrinal. In comparison to vehicle, Sal-003 restored LTD ( Figure 4B ) and to levels that once again approximate the normal magnitude ( Figures 4B and  4C ). These observations demonstrate that eIF2a signaling normally plays a role in brain processes that are disrupted in DYT1 model mice and that acute enhancement of eIF2a phosphorylation is sufficient to restore normal brain plasticity to disease model mice.
Enhancing eIF2a Signaling Improves Neonatal Survival of Homozygous DYT1 Mice
The findings thus far provide strong support for roles of the eIF2a signaling pathway in normalizing in vitro cellular (Figures 1, 2 , and 3) and ex vivo brain phenotypes related to the DYT1 genotype (Figure 4) . We next sought to determine whether targeting eIF2a signaling would significantly affect the in vivo deleterious consequences of the DYT1 TOR1A mutation. Although etiological mouse models of DYT1 dystonia have not had robust dystonic phenotypes (Dang et al., 2005; Tanabe et al., 2012) (a finding we believe may be related to the low genetic penetrance of this disorder among other factors), we took advantage of another deleterious genotype-dependent effect of the mutation to examine this question, neonatal lethality of homozygous delGAG knockin mice Tanabe et al., 2012) . To this end, we administered salubrinal or vehicle daily to pregnant dams (in Tor1a delGAG/+ 3 Tor1a delGAG/+ breedings) from approximately embryonic day 10 through delivery and tested its effects on neonatal survival. In comparison to litters from vehicle-treated dams, salubrinal dramatically reduced DE/ DE pup mortality ( Figure 4D ). Additionally, there was no evidence that salubrinal had a non-specific mechanism in improving neonatal survival, as no mortality differences were observed between treatment and control groups in the remaining pups of either wild-type or heterozygote genotypes ( Figure 4D ). Although in this study design there was no postnatal salubrinal treatment except possibly through lacteal transfer (though homozygous DE/DE pups are known to not nurse; , we anecdotally observed that two salubrinal-treated homozygous DE Torsin1a pups survived through the second postnatal day. No vehicle-treated homozygous pups survived through even the first postnatal day.
Stress-Induced eIF2a Signaling Is Impaired in Human DYT1 Patient Fibroblasts
Having established the ability of eIF2a modulators to both normalize and reproduce a number of DYT1-genotype related phenotypes, a key remaining question is whether the eIF2a signaling pathway is actually disrupted in DYT1 dystonia. To address this, we examined the integrity of the eIF2a signaling pathway in fibroblasts derived from human DYT1 patients. We measured the stress-induced increase in ATF4 expression as a readout of pathway activation. In line with our predictions of impaired signaling in DYT1, we found that ATF4 upregulation in response to the potent ER stressor thapsigargin was attenuated in DYT1 patient-derived fibroblasts ( Figures 5A and 5B) . 
DYT1 Patient Cells have Increased Basal Levels of a Negative Feedback Regulator of the eIF2a Pathway
Because we found the stress-induced response of ATF4 translation was still present, but attenuated in DYT1 patient cells, we considered whether DYT1 might be associated with an increase in negative feedback mechanisms that attenuate phosphoeIF2a signaling. The principal negative feedback proteins in the eIF2a pathway are the eIF2a phosphatase subunits, CReP and GADD34. A role for CReP was suggested by our pharmacological studies in which salubrinal (which inhibits both CReP and GADD34), but not guanabenz (a more specific inhibitor of GADD34) corrected DE Torsin1a mislocalization. We therefore measured levels of CReP under basal and ER-stressed conditions. We found two striking differences in CReP levels between fibroblasts from DYT1 patients and healthy controls. First, basal CReP levels were significantly higher in fibroblasts from DYT1 patients ( Figures 4C and 4D ), supporting the negative feedback hypothesis. Second, whereas CReP levels in normal fibroblasts robustly increased after treatment with thapsigargin as expected ( Figure 4E ), CReP levels in DYT1 patient fibroblasts were unresponsive to the treatment. As the increase in CReP levels in response to stress is regulated by phospho-eIF2a-dependent translation (Andreev et al., 2015) , the failure of CReP levels to rise provides additional evidence that eIF2a pathway signaling is deficient in DYT1. Altogether, these results provide evidence from human patient cell lines that eIF2a signaling is not only a novel therapeutic inroad, but is also disrupted in DYT1 dystonia. The specific disruptions of steady-state and induced CReP levels further suggest a specific pathway impairment mechanism in DYT1 dystonia whereby basally increased levels of negative feedback proteins attenuate acute phasic eIF2a signaling.
Identification of a Loss-of-Function ATF4 Mutation in Sporadic Cervical Dystonia Patients
Interestingly, the gene associated with another rare inherited dystonia supports our findings indicating a role for deficient eIF2a signaling in DYT1 dystonia pathogenesis. Mutations in the PRKRA gene, which encodes an upstream eIF2a kinase activator (Figure 2A ), cause DYT16 dystonia (Camargos et al., 2008) . Moreover, recent functional evidence indicates that the most common PRKRA mutation delays and reduces eIF2a phosphorylation (see Figure 5 in Vaughn et al., 2015) . Considering the intersection of DYT16 and DYT1 dystonia at the eIF2a pathway, we hypothesized that eIF2a pathway dysfunction might also contribute to other forms of dystonia.
To investigate this possibility, we first reviewed results from a pilot study we had performed on WES obtained from 20 individuals of European ethnicity with sporadic, isolated dystonia (mean age of onset 47.4 ± 9.6 years; Table S3 ). In these exomes, we performed an unbiased, exome-wide analysis to identify exons where rare (ExAC European ethnicity MAF <0.5%) coding variants were found in at least two cases and no controls (we utilized 571 controls of European ethnicity sequenced in-house using the same capture kit as the cases). We found that exome wide, only 12 exons met these criteria ( Figure 6A) .
Notably, one of these exons was in the gene for the phosphoeIF2a effector, ATF4. It is notable that the implicated exon, exon 1, encodes the amino terminal region of ATF4, which appears to have roles in recruitment of transcriptional co-factors (Ché rasse et al., 2007) , whereas the other exon in this gene, exon 2, encodes the canonical basic leucine-zipper DNA binding domains. We found that the same exon 1 rare variant was present in two cases (n.22:39917587C/T [GRCh37/hg19], rs111719524, p.P46L). Additionally, both P46L subjects had the same form of dystonia, cervical dystonia. Neither subject knew of any family history of dystonia.
Enrichment of Rare ATF4 Coding Mutations in Sporadic Cervical Dystonia
To prospectively test whether enrichment of rare coding variants in ATF4 could be replicated in a large cohort, we Sanger sequenced ATF4 exon 1 in an additional 239 sporadic cervical dystonia cases. In total, we found that 3.3% of cases (8 of 239) had rare functional variants, compared to 0.5% of controls of European ethnicity in the ExAC database (OR 6.8, p = 4.1 3 10 À5 ; Figure 6B ). Of the new cases, 223 self-identified as Caucasian with non-Hispanic/Latino ethnicity (see Table S4 ). Of the 16 other cases, one Latino case had a qualifying variant, which was P46L. Interestingly, P46L is found at a frequency of 0.2% in those with European ethnicity in the ExAC database, but at an even lower frequency in all other ethnicities in ExAC, for example, a minor allele frequency (MAF) of 0.02% in Latinos and 0.12% overall. In addition to the three new P46L cases, another four cases were identified with qualifying variants affecting the same amino acid (D35), with two different mutations affecting this site ( Figure 6B ). D35 was mutated in only one sample in ExAC (of Latino descent) for an overall incidence of less than 0.0008%. While the D35N variant is classified as ''probably damaging'' by PolyPhen2, it is notable that this residue is highly evolutionarily conserved ( Figure S7 ), and both variants are strongly predicted to alter phosphorylation of a nearby tyrosine, Y37 ( Figure 6D ). Finally, a single case had a variant involving the start methionine, a location clearly suggesting a deleterious effect. Interestingly, although the functions of the N-terminal portion of ATF4 are not fully understood, the histone acetyltransferase p300-a transcriptional co-activator-binds ATF4 within the first 85 amino acids (Lassot et al., 2005) , a region which contains all of the rare variants we identified ( Figure 6B , bottom, purple bar and red dots). Lastly, it is notable that the common ATF4 polymorphism Q22P, present in approximately one third of the human population (http://www. exac.broadinstitute.org), is not predicted to have a deleterious effect on gene function and was not enriched in our cervical dystonia patients ( Figure 6B ). Thus, this enrichment appears specific to rare ATF4 variations that are likely gene disrupting.
Functional Characterization of Rare ATF4 Variants in Sporadic Cervical Dystonia
To evaluate the functional significance of the identified rare variants, we tested their transcriptional activation activity using a luciferase reporter driven by the ATF4-sensitive amino acid response element (AARE) . As controls, we tested the activity of WT ATF4 and the DNA binding-dead ATF4 R296K (Aukerman et al., 1991) . As expected, overexpression of WT ATF4 caused robust expression of the luciferase reporter, while expression of the DNA binding-dead ATF4 R296K had no significant effect (Figure 6C , left; R296K versus empty vector, p = 0.89). Surprisingly, we found that the M1V variant of ATF4 did not significantly alter function. However, in this experimental setting, the presence of an N-terminal epitope tag (also M1V mutated) and the absence of the endogenous upstream regulatory elements for ATF4 translation confound interpretation of the significance of this finding. It is notable that ATF4 does contain methionine residues at positions 4 and 17, which might serve as alternative start sites. Apart from M1V, the remaining coding mutations identified in sporadic cervical dystonia cases (P46L, D35N, and D35Y) all showed significantly reduced activity, consistent with the direction of eIF2a pathway impairment that would be predicted by the effects described in DYT1 here and DYT16 (Vaughn et al., 2015) . We also tested the most common ATF4 variant in the general population, Q22P, and found that rather than impair, it showed modestly enhanced activity relative to WT. We were struck by the relative effects of the D35N and D35Y substitutions because they mirrored bioinformatic predictions of phosphorylation likelihood at a nearby tyrosine (Y37). Since ATF4 is known to be regulated by other posttranslational modifications, but not by tyrosine phosphorylation (Pakos-Zebrucka et al., 2016), we made a conservative amino acid substitution, Y37F, to directly test the functional significance. Strikingly, severe functional effects were observed that approximated the negative control conditions (n.s. versus empty vector and R296K). These results suggest the intriguing possibility that Y37 may be an important previously unrecognized site for ATF4 regulation by phosphorylation and that impaired activity of D35 variants found in cervical dystonia may act through modulating Y37 phosphorylation. In summary, these functional observations, combined with the human genetic association validated in a second independent cohort, provide strong evidence that deficient eIF2a signaling contributes not only to rare inherited dystonias, but also to sporadic forms of adult-onset, cervical dystonia.
DISCUSSION
Using an unbiased genome-wide RNAi screen employing a novel high-throughput, DYT1 dystonia assay for Torsin1a mislocalization as an entry point, we have discovered a role for deficient eIF2a pathway signaling in dystonia pathogenesis that provides a common mechanism bridging multiple distinct forms of the disease. Although knowledge of genetic causes for isolated dystonia is rapidly increasing, the identification of specific pathomechanisms for dystonia has been far more challenging (Lohmann and Klein, 2013) . To date, dopamine deficiency is the only known common cellular mechanism with strong support across multiple forms of dystonia (Lohmann and Klein, 2013; Waugh and Sharma, 2013) .
eIF2a Pathway Hypothesis for Dystonia
Although the specific disruptions in the eIF2a pathway are distinct among these three dystonias, they converge upon a common consequence of reduced eIF2a pathway signaling Table S5 ). The ATF4 protein schematic showing rare variant locations (red dots) is shown on the bottom. (C) Transcriptional activation activity of mutant ATF4 constructs, as measured by a luciferase reporter under transcriptional control of an AARE-RLuc. The data were normalized such that luciferase activity after WT ATF4 transfection = 1. *p < 0.05 and ***p < 0.0005 versus WT ATF4 condition by unpaired t test. n = 28 (vector, WT, Q22P, and P46L), 18 (R269K, D35N, and D35Y), 12 (M1V) , and 6 (Y37F) independent experiments. The P46L condition was measured in separate groups of 10 and 18 experiments, each of which independently reached p < 0.005 significance. All of the data are presented as means ± SEM. (D) Homology-based prediction of the likelihood of Y37 phosphorylation in WT, D35N, and D35Y ATF4 (www.cbs.dtu.dk/services/NetPhos).
( Figure 7) . In DYT1 patient-derived fibroblasts, we find an attenuated ISR alongside high basal levels of a negative feedback regulator of eIF2a phosphorylation, the CReP/PPP1R15B phosphatase ( Figures 5 and 7, red) . In sporadic cervical dystonia patients, we find significant enrichment of rare ATF4 missense variants that reduce transcriptional activity (Figures 6 and 7, green) . Transcriptional regulation by ATF4 is a major downstream effector of the ISR (Pakos-Zebrucka et al., 2016) . In DYT16, it is noteworthy that the most common PRKRA mutation is associated with both delayed and decreased stress-induced phosphorylation of eIF2a (see Figure 5 in Vaughn et al., 2015) (Figure 7 , orange) among other effects, such as promoting apoptosis, which has been suggested by Vaughn and colleagues as a pathomechanism. Lastly, while PRKRA's function as an activator of eIF2a kinases is well-described, additional functions have also been reported (Lee et al., 2006; Yong et al., 2015) . Thus, our results in DYT1 models and the genetics of sporadic cervical dystonia provide supportive evidence that PRKRA's role in eIF2a signaling is likely relevant for DYT16 pathogenesis. Taken together, these observations create a specific mechanistic model to test the hypothesis that impaired eIF2a signaling is a central mechanism for dystonia.
The failure of etiological dystonia models to reproduce dystonia symptomatology has been a major impediment to studying dystonia mechanisms, and the reasons for this barrier are not yet clear. Our implication of a stress response pathway provides one possible explanation, the need for a second hit that activates this pathway. While the convergence of human genetic associations at PRKRA and ATF4 provide genetic support that pathway dysfunction can lead to dystonia in humans, a limitation of the present study is that we were unable to examine the effects of targeting this pathway on dystonia in DYT1 mouse models with construct validity because they lack dystonic movements. Rather, we find that eIF2a pathway dysfunction is present in DYT1 patient fibroblasts and leads to abnormal synaptic plasticity in DYT1 model mice, and that enhancing eIF2a signaling mitigates homozygous lethality due to the DYT1 mutation. Thus, an important future direction will be to demonstrate whether and when targeting eIF2a signaling can improve dystonia. An important related question will be to determine exactly where in the brain selective vulnerability to altered eIF2a signaling occurs and how it leads to dystonia. Both the relevant brain regions and specific cell types involved in dystonia are open areas of debate. Based on the eIF2a hypothesis, future identification of cell subtypes and brain regions with eIF2a pathway disruption considered in conjunction with other lines of evidence implicating specific cells and circuits may help accelerate this effort and enable conditional genetic tests.
eIF2a Mechanisms for Brain Dysfunction in Dystonia ER stress and altered proteostasis, as could arise from eIF2a signaling perturbations, are widely considered potential mechanisms for selective brain vulnerability (Zhao and Ackerman, 2006) . Besides having commonalities as being components of the ISR, it is notable that in the brain, both eIF2a phosphorylation and ATF4 are also linked to expression of long-term forms of synaptic plasticity (Bartsch et al., 1995; Costa-Mattioli et al., 2007; Di Prisco et al., 2014; Trinh and Klann, 2013) . In dystonia, a role for pathological plasticity has long been suggested by both clinical features, such as task-specific dystonias that occur only while performing a specific learned task and the relatively delayed time course of response to deep brain stimulation (Peterson et al., 2010) and findings of altered synaptic plasticity in dystonia animal models (Kö hling et al., 2004; Martella et al., 2009) .
In this study, we find evidence that the significance of eIF2a pathway dysfunction for dystonia could be related to its brainspecific role in regulating synaptic plasticity. Lack of corticostriatal mGluR5-LTD is a well-described phenotype in DYT1 mouse models (Martella et al., 2009) . Previously, eIF2a phosphorylation had been shown to be necessary for hippocampal mGluR-LTD (Di Prisco et al., 2014) . We have expanded this role to include mGluR5-LTD at cortical synapses onto projection neurons (Figure 4A) . In addition to reproducing the DYT1 phenotype with signaling blockade in WT mice, we also find that augmenting eIF2a phosphorylation rescued plasticity in DYT1 model mice ( Figure 4B ). However, since it remains to be established that abnormal striatal plasticity per se is a causative feature for dystonia pathogenesis, it is important to recognize that other as yet unidentified functions of eIF2a signaling in the brain may instead be the most significant for its role in dystonia pathogenesis.
DE Torsin1a and eIF2a Pathway Dysfunction
An in-frame deletion of a DE is the basis for the autosomal dominant TOR1A mutation that causes DYT1 dystonia (Ozelius et al., 1997) . Among various cellular effects ascribed to Torsin1a or the mutant protein, several groups have found alterations in ER stress response indicators though not specifically in the eIF2a pathway and typically in the setting of overexpression paradigms Nery et al., 2011) . In this study, once eIF2a signaling was suggested by the genome-wide RNAi screen (Table 1) , its role was supported in two settings with endogenous, heterozygous delGAG TOR1A gene expression, patient fibroblast cell lines ( Figures 1K and 5 ) and DYT1 knockin mice (Figure 4) . A principal observation made in DYT1 patient fibroblasts was the finding of elevated steady-state levels of the eIF2a phosphatase, CReP ( Figure 5D ), and its lack of upregulation upon pathway activation as is normally seen (Figure 5E ). Determining exactly how mutant Torsin1a leads to this pathway perturbation is an important future direction.
ATF4 Contributions to Sporadic Focal Dystonia
As with many other diseases with both sporadic and inherited forms, the genetic contributions to sporadic dystonia are the least well understood. The large majority of dystonia cases are sporadic and of unknown cause, with only 10% of cases reporting an affected family member (LeDoux, 2012) . In this study, we found that 3% of patients with one of the most common sporadic dystonias, cervical dystonia, had functionally significant, rare missense variants in the ATF4 gene. The focus on this gene arose as a result of an unbiased exome analysis in which 2 of 20 cases shared a mutation ( Figure 6A ). While independent confirmation of this association in a second cohort establishes the enrichment, our findings raise two important future questions. The first is to determine whether other genes in this pathway are involved and in which dystonia populations. The second is to understand the mechanism of the genetic contribution to dystonia, as a risk factor or causative allele? And whether there is a need for a second hit to lead to dystonia. Certainly a two-hit model is suggested by the presence of reduced penetrance in many of the monogenic isolated dystonias (Lohmann and Klein, 2013) . Attenuated activity of a major cellular stressresponse pathway, the ISR, might be one mechanism for this piece of the clinical puzzle.
The eIF2a Pathway as a Diagnostic and Therapeutic Target In all, our findings point to the eIF2a pathway as a promising biological target to aid in the development of diagnostic tools and disease-modifying treatments for dystonia. Genetic and functional phenotyping for impairment of eIF2a pathway signaling could prove useful for identifying cohorts of patients with similar underlying mechanisms/risk factors. Encouragingly, we found that pharmacologically enhancing eIF2a signaling rescued synaptic plasticity and delayed perinatal mortality (Figure 4) . However, since the relationship of these two phenotypes to dystonia is unclear, further studies are warranted. Interestingly, the results of our study, by showing distinct insults to a common pathway across different dystonias (Figure 7 ), suggest that it may be necessary to develop therapies targeting multiple portions of the eIF2a pathway.
EXPERIMENTAL PROCEDURES
For additional experimental details and tables listing reagents used in this study, please see Supplemental Experimental Procedures.
Torsin1a Localization Assay
Flp-In T-REx 293 cells inducibly expressing either EGFP-WT or -DE Torsin1a were plated, transfected, induced, fixed, and imaged in 384-well glass-bottom plates (Corning). Transfection of siRNA pairs from the QIAGEN Human Genome siRNA Library v1.0 in two unique pools per gene were performed as earlier described (Barrows et al., 2010) . Fixed and Hoechst-stained cells were imaged on a Cellomics ArrayScan automated high-content imaging system. Images were analyzed using a modification of the Cellomics ArrayScan V Compartment AnalysisV2 protocol. Similar protocols were used for pharmacological and ATF4 overexpression experiments. Animals DE Torsin1a knockin (courtesy of Dr. W. Dauer, University of Michigan) and Drd1a-tdTomato line 6 (Ade et al., 2011) mice on C57BL/ 6 background were bred in standard housing conditions with food and water provided ad libitum. All procedures were approved by the Duke University Institutional Animal Care and Use Committee (IACUC).
Electrophysiological Recordings
Acute horizontal brain slices from the progeny of heterozygous DE Torsin1a knockin 3 homozygous Drd1a-tdTomato mice (age P15-21) were prepared largely as described in Trusel et al. (2015) . LTD was induced as in Trusel et al. (2015) with modifications noted in Supplemental Experimental Procedures.
Human Dystonia Patients
Whole-Exome Sequencing Subjects Genomic DNA samples from 20 subjects with sporadic dystonia were exome sequenced. Results were compared to sequences from 571 control samples that were sequenced as part of other studies at Duke University. All studies were reviewed and approved by the Duke University Medical Center IRB, and all subjects gave written informed consent. Dystonia subjects were recruited at the Movement Disorders Center at Duke University Medical Center, Durham, NC. ATF4 Exon 1 Sequencing Subjects Genomic DNA samples were acquired from subjects recruited at Movement Disorder Centers in New York (Mount Sinai Beth Israel) and Boston (Massachusetts General Hospital) and from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (https://catalog.coriell.org/1/NINDS). The local institutional review boards approved the studies and all participating individuals gave informed consent prior to participation. NINDS Repository sample numbers corresponding to the samples used are listed in Supplemental Experimental Procedures.
ATF4 Activity Assay
HEK293T cells were transfected with pAARE-RLuc, pCMV-CLuc2, and empty vector or FLAG-tagged WT/mutant ATF4 as appropriate. The following day conditioned media was harvested and the assay cells were lysed. Conditioned media and cell lysates were assayed for CLuc and RLuc using Cyperidina Luciferase (NEB) and Renilla Luciferase (Thermo Fisher) assay kits.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.neuron.2016.11.012.
AUTHOR CONTRIBUTIONS
Z.F.C. designed and conducted the whole-genome RNAi screen and performed all patient cell line luciferase and western blot assays. R.H.-M. performed the electrophysiological experiments. J.E.R. designed and conducted all other experiments. M.K.S., S.M.S., A.Y.L., C.X., S.T., and K.K.T. assisted with experiments. N.C., P.H., J.J., B.S., M.S., R.S.-P., S.B., K.S., and N.S. recruited subjects with dystonia. L.J.O. contributed to the design and interpretation of genetic analyses. E.T.C. performed genetic analyses of whole-exome and ATF4 sequences. J.L.P. assisted in the implementation of the RNAi screen. N.C. provided input to all phases of the study. J.E.R. and N.C. wrote the manuscript.
